福安藥業(300194.SZ)臨近午間收盤拉昇 羥氯喹獲批在美投入臨牀試驗治療新冠
格隆匯4月21日丨羥氯喹概念股福安藥業(300194.SZ)在11點後出現直線拉昇走勢,股價由跌轉升,截至半日收盤報6.95元,漲2.81%,暫成交4.47億元,最新總市值83.69億元。瑞士製藥商諾華公司4月20日證實,抗瘧藥物羥氯喹已經獲批在美國投入臨牀試驗,以檢驗它對新型冠狀病毒是否有效。值得注意的是,在港A兩地同時上市的上海醫藥也涉及羥氯喹產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.